These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2935549)

  • 1. Doxazosin determination by high-performance liquid chromatography using fluorescence detection.
    Cowlishaw MG; Sharman JR
    J Chromatogr; 1985 Nov; 344():403-7. PubMed ID: 2935549
    [No Abstract]   [Full Text] [Related]  

  • 2. Liquid chromatographic analysis of doxazosin in human serum with manual and robotic sample preparation.
    Fouda HG; Twomey TM; Schneider RP
    J Chromatogr Sci; 1988 Nov; 26(11):570-3. PubMed ID: 2976067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of terazosin in human plasma, using high-performance liquid chromatography with fluorescence detection.
    Sekhar EC; Rao TR; Sekhar KR; Naidu MU; Shobha JC; Rani PU; Kumar TV; Kumar VP
    J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):137-42. PubMed ID: 9686880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection.
    Rubin PC; Brunton J; Meredith P
    J Chromatogr; 1980 Nov; 221(1):193-5. PubMed ID: 6450219
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of a solid-phase extraction high-performance liquid chromatographic assay for doxazosin.
    Jackman GP; Colagrande F; Louis WJ
    J Chromatogr; 1991 May; 566(1):234-8. PubMed ID: 1679435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of tiodazosin in plasma and whole blood by high-performance liquid chromatography.
    Mico BA; Baughman RA; Benet LZ
    J Chromatogr; 1982 Jun; 230(1):203-6. PubMed ID: 7107763
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detection.
    Patterson SE
    J Chromatogr; 1984 Nov; 311(1):206-12. PubMed ID: 6520165
    [No Abstract]   [Full Text] [Related]  

  • 8. Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α
    Omar MA; Hammad MA; Salman BI
    Luminescence; 2018 Nov; 33(7):1226-1234. PubMed ID: 30094938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacological studies with doxazosin.
    Elliott HL; Meredith PA; Vincent J; Reid JL
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):27S-31S. PubMed ID: 2871854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of tiodazosin concentrations in human plasma with a fluorescence high-performance liquid chromatographic method.
    Forgue ST; Van Harken DR; Smyth RD
    J Chromatogr; 1985 Jul; 342(1):221-7. PubMed ID: 4044753
    [No Abstract]   [Full Text] [Related]  

  • 11. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
    Frick MH; Halttunen P; Himanen P; Huttunen M; Pörsti P; Pitkäjärvi T; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):55S-62S. PubMed ID: 2939868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection.
    Sripalakit P; Nermhom P; Saraphanchotiwitthaya A
    J Chromatogr Sci; 2005 Feb; 43(2):63-6. PubMed ID: 15826362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension.
    Fukiyama K; Omae T; Iimura O; Yoshinaga K; Yagi S; Inagaki Y; Ishii M; Kaneko Y; Yamada K; Ijichi H
    Am Heart J; 1991 Jan; 121(1 Pt 2):317-22. PubMed ID: 1824654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prazosin determination by high-pressure liquid chromatography using fluorescence detection.
    Yee YG; Rubin PC; Meffin P
    J Chromatogr; 1979 Apr; 172():313-8. PubMed ID: 548534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
    de Planque BA
    Am Heart J; 1991 Jan; 121(1 Pt 2):304-11. PubMed ID: 1670744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure.
    Bailey RR; Nairn PL; Walker RJ
    N Z Med J; 1986 Dec; 99(815):942-5. PubMed ID: 2949169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism and kinetics of doxazosin in man, mouse, rat and dog.
    Kaye B; Cussans NJ; Faulkner JK; Stopher DA; Reid JL
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):19S-25S. PubMed ID: 2939865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):69S-75S. PubMed ID: 2939870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.